Prot #MER-XMT-1660-1: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors

Project: Research project

Project Details

StatusActive
Effective start/end date1/30/24 → 1/30/27

Funding

  • PSI Pharma Support America Inc. (Prot #MER-XMT-1660-1 // Prot #MER-XMT-1660-1)
  • Mersana Therapeutics, Inc. (Prot #MER-XMT-1660-1 // Prot #MER-XMT-1660-1)